Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis

European Journal of Clinical Microbiology & Infectious Diseases

Volumn 14, Issue 4, 1995, Pages 291-296

  Gaillard, J L ^a   Cahen, P ^a   Delacourt, C ^a   Silly, C ^a   Le Bourgeois, M ^a   Coustere C ^a   de Blic, J ^a   Lenoir, G ^a   Scheinmann, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; IMIPENEM; NETILMICIN; TICARCILLIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, AMINOGLYCOSIDE; ANTIBIOTICS, COMBINED; ANTIBIOTICS, LACTAM; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMAN; INFANT; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; RESPIRATORY TRACT INFECTIONS; SERUM BACTERICIDAL TEST; SPUTUM; TREATMENT OUTCOME;

EID: 0029032164     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/BF02116521     Document Type: Article

References (31)

1. Cystic fibrosis
2. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis
3. Pseudomonas colonization in cystic fibrosis. A study of 160 patients
4. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction
5. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal
6. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials
7. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis
8. Antimicrobial chemotherapy in cystic fibrosis patients
9. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
10. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
11. Serum bactericidal test as a prognostic indicator in acute pulmonary exacerbations of cystic fibrosis
12. Assay of ceftazidime in biological fluids using high-pressure liquid chromatography
13. Determination of ticarcillin levels in serum by high-pressure liquid chromatography
14. The measurement of antibiotics in human body fluids: techniques and significance
15. Disk susceptibility test
16. Susceptibility testing of antibiotics in liquid media
17. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data
18. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests
19. Bacteriological effects of anti- Pseudomonas aeruginosa chemotherapy in cystic fibrosis
20. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo
21. A double-blind controlled trial of anti- Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis
22. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
23. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis
24. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis
25. Imipenem/cilastatin, an alternative treatment of Pseudomonas infection in cystic fibrosis
26. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis
27. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum
28. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum
29. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin
30. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis